Q-omics provides the consensus-scored KLK14 profile across patient tissues and cancer cell-line models. KLK14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLK14 is differentially expressed in 12, with the highest sampling consensus in BRCA. Additionally, KLK14 RNA expression shows 14,330 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BRCA, and UVM as cancer lineages where KLK14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK14 survival associations across molecular data types. KLK14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK14 RNA expression–survival associations across cancer types. High KLK14 expression shows unfavorable associations in KIRC, ACC, THCA, LGG and UCS, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLK14 RNA expression.
This table summarizes KLK14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLK14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK14 shows lower tumor expression in BRCA and LUAD and higher tumor expression in KIRC, LUSC, KICH and HNSC. The BRCA box plot shows higher KLK14 RNA expression in normal versus tumor tissue (log2 FC = −1.229, t-test p < 0.001).
This table shows molecular features associated with KLK14 in patient tissues and cancer cell lines. In patient samples, KLK14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
